Investor Presentaiton

Innovative carrier to break serotype composition ceiling Introducing new carrier for 4 serotypes to improve performance Robust performance of the 4 serotypes conjugated to TT Post Dose 4: IgG GMC ratio 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F 8 9N 10A 11A 12F 15B 22F 33F PCV13 PCV21 Carrier protein TT Carrier protein CRM 197 GMC ratio vs Prevnar 13 16 0,25 1 5 PCV21 Phase 2 PCV21 Phase II [NCT04398706] Seroresponse: IgG concentration 20.35 µg/mL for all serotypes PCV20 Phase III [NCT04382326] Seroresponse: IgG concentration ≥0.35 μg/mL for all serotypes except ≥ 0.23 μg/mL, ≥0.10 μg/mL and ≥ 0.12 µg/mL for serotypes 5, 6B and 19A respectively Note: for serotypes 15B and 22F, difference (% and GMC ratio) vs lowest serotype in Prevnar 13 DISCLAIMER: data from separate studies should be interpreted with care. 66 Vaccines Investor Event 15B PCV20 Phase 3 22F sanofi

View entire presentation